抗がん剤市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、薬剤別、投与経路別、エンドユーザー別、地域別、競合別、2019-2029年

抗がん剤の世界市場規模は2023年に1,725億2,000万米ドルとなり、2029年までの予測期間のCAGRは5.25%で着実な成長が予測されています。

がんは依然として世界の健康課題であり、毎年数百万人の命に影響を及ぼしています。効果的な治療法の絶え間ない追求において、世界の抗がん剤市場は重要なプレーヤーとして浮上しています。この市場は、画期的な研究と技術の進歩に後押しされ、がん治療薬の展望を形作る上で極めて重要な役割を果たしています。世界の抗がん剤市場は、高齢化、ライフスタイルの変化、がんに対する意識の高まりなどの要因によって、近年著しい成長を遂げています。各種市場レポートによると、市場は今後も上昇基調を維持し、収益と技術革新の両面で新たな高みに達すると予想されています。免疫療法は、がん治療のゲームチェンジャーとして登場しました。免疫チェックポイント阻害剤やキメラ抗原受容体（CAR）T細胞療法などの治療法が広く受け入れられています。同市場では、治療効果の向上と副作用の軽減を目指し、新規免疫治療薬の研究開発への投資が増加しています。

プレシジョンメディシンの時代は、がん治療にパラダイムシフトをもたらしました。患者の遺伝的体質やがんの分子的特徴に基づいて治療法を調整することが、ますます一般的になってきています。この個別化されたアプローチは、治療成績を向上させるだけでなく、副作用を最小限に抑えます。標的療法は、抗がん剤開発の焦点であり続けています。がんの増殖や進行に関与する特定の分子を標的とするように設計された低分子阻害剤やモノクローナル抗体が大きな成功を収めています。市場は、さまざまながん種で標的療法の開発が急増しています。

主な市場促進要因

がん罹患率の増加

研究開発投資の増加

主な市場課題

医薬品開発コストの上昇

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（乳がん、血液がん、前立腺がん、消化器がん、婦人科がん、肺がん、その他）
  • 薬剤別（細胞毒性薬、ホルモン療法、標的療法、その他）
  • 投与経路別（経口、非経口、その他）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ

第5章 アジア太平洋地域の抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 薬剤別
  • 投与経路別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 薬剤別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 薬剤別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 薬剤別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの抗がん剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 薬剤別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の抗がん剤市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 医薬品業界の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Company（India）Pvt. Ltd.
• AstraZeneca plc
• Sanofi S.A.
• Bayer AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Anticancer Drug Market was valued at USD 172.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Cancer remains a formidable global health challenge, affecting millions of lives annually. In the relentless pursuit of effective treatment options, the global anticancer drug market has emerged as a critical player. This market, fueled by groundbreaking research and technological advancements, plays a pivotal role in shaping the landscape of cancer therapeutics. The global anticancer drug market has witnessed significant growth in recent years, driven by factors such as an aging population, lifestyle changes, and increased awareness of cancer. According to various market reports, the market is expected to continue its upward trajectory, reaching new heights in terms of both revenue and innovation. Immunotherapy has emerged as a game-changer in cancer treatment. Therapies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have gained widespread acceptance. The market is witnessing increased investment in research and development for novel immunotherapeutic agents, aiming to enhance treatment efficacy and reduce side effects.

The era of precision medicine has brought about a paradigm shift in cancer treatment. Tailoring therapies based on a patient's genetic makeup and the molecular characteristics of their cancer has become increasingly common. This personalized approach not only improves treatment outcomes but also minimizes adverse effects. Targeted therapies continue to be a focal point in anticancer drug development. Small molecule inhibitors and monoclonal antibodies designed to target specific molecules involved in cancer growth and progression have demonstrated significant success. The market is witnessing a surge in the development of targeted therapies across various cancer types.

Key Market Drivers

Increasing Cancer Incidence

In recent years, the global healthcare landscape has been grappling with an alarming surge in cancer incidence. This rise in cancer cases has prompted an unprecedented demand for advanced and effective anticancer drugs. As the world faces the challenges posed by the increasing prevalence of cancer, the pharmaceutical industry is stepping up its efforts to develop innovative therapies, driving the growth of the global anticancer drug market. Cancer continues to be a major public health concern, with millions of new cases diagnosed each year across the globe. Several factors contribute to the escalating rates of cancer. Lifestyle choices such as tobacco use, unhealthy diets, lack of physical activity, and exposure to environmental carcinogens play a significant role. An aging population, with an increased life expectancy, contributes to a higher prevalence of cancer.

Increased Investment in Research and Development

The global anticancer drug market has witnessed significant growth in recent years, due to a surge in research and development (R&D) investments dedicated to combating the complex and challenging realm of cancer. As scientists delve deeper into understanding the intricacies of cancer biology, new therapeutic approaches are emerging, leading to the development of innovative anticancer drugs. The increased investment in R&D is a driving force behind the development of novel anticancer drugs. Pharmaceutical companies are allocating substantial budgets to support groundbreaking research initiatives, enabling the exploration of diverse therapeutic avenues. This influx of funds has allowed researchers to pursue innovative strategies, including targeted therapies, immunotherapies, and precision medicine tailored to individual patient profiles. Targeted therapies have emerged as a game-changer in the field of cancer treatment. These drugs are designed to specifically target cancer cells, sparing healthy cells and minimizing side effects. The development of targeted therapies is intricately linked to the understanding of molecular and genetic abnormalities driving cancer growth. R&D investments have enabled scientists to identify and exploit these abnormalities, leading to the creation of drugs that interfere with specific cancer-promoting mechanisms.

Immunotherapy has gained prominence as a revolutionary approach to cancer treatment. By leveraging the body's immune system to recognize and destroy cancer cells, immunotherapies have shown remarkable efficacy in certain cancer types. Research investments have fueled the development of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines, providing new hope for patients with previously limited treatment options. Precision medicine represents a paradigm shift in cancer treatment, emphasizing the customization of therapies based on a patient's unique genetic and molecular profile. R&D investments have facilitated the identification of biomarkers and the development of diagnostic tools that enable oncologists to match patients with the most effective treatments. This personalized approach enhances treatment outcomes and reduces the likelihood of adverse reactions. The impact of increased R&D investments is not confined to a specific region but reverberates globally. Collaborations between academic institutions, pharmaceutical companies, and research organizations across borders are fostering a collaborative environment that accelerates progress. As a result, patients worldwide are gaining access to cutting-edge anticancer therapies, contributing to a more equitable distribution of advanced medical interventions.

Key Market Challenges

Rising Costs of Drug Development

The process of developing a new anticancer drug is lengthy, complex, and expensive. It typically begins with extensive preclinical research, where potential compounds are tested in laboratories to assess their safety and efficacy. This phase alone requires substantial financial investment in personnel, equipment, and facilities. Following successful preclinical studies, drugs move to clinical trials, which are conducted in multiple phases involving human subjects. These trials are not only time-consuming but also expensive, with costs skyrocketing due to the need for large patient populations, extensive monitoring, and adherence to rigorous regulatory standards. According to estimates, it can take over a decade and cost billions of dollars to bring a single drug from discovery to market approval.

Stringent regulatory standards set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) add another layer of complexity and cost to the drug development process. Meeting these standards is essential for ensuring the safety and efficacy of anticancer drugs, but the associated compliance efforts demand substantial financial resources. As the understanding of cancer biology advances, regulatory requirements for demonstrating clinical benefit become more demanding. This evolution contributes to an increase in the size and duration of clinical trials, further elevating the overall costs of drug development. The pharmaceutical industry operates in a high-risk environment where a significant percentage of drug candidates fail at various stages of development. The risks associated with drug development, coupled with the prolonged timelines and escalating costs, can deter potential investors. This risk aversion may lead to fewer resources being allocated to anticancer drug research and development, ultimately limiting the number of new therapies entering the market.

The rising costs of drug development have a direct impact on the pricing of anticancer drugs. Pharmaceutical companies often pass on the expenses incurred during the development process to end-users, including patients, healthcare providers, and payers. As a result, the affordability of these life-saving medications becomes a concern, and access to innovative therapies may be restricted, particularly in lower-income regions.

Key Market Trends

Technological Advancements

In recent years, the field of oncology has witnessed a paradigm shift in the way cancer is diagnosed and treated, due to rapid advancements in technology. The global anticancer drug market is experiencing a transformative phase, with innovative technologies playing a pivotal role in shaping the future of cancer therapeutics. From precision medicine and targeted therapies to artificial intelligence (AI) and immunotherapy, these technological breakthroughs are not only improving patient outcomes but also driving significant growth in the global anticancer drug market. One of the key drivers behind the growth of the global anticancer drug market is the advent of precision medicine and targeted therapies. Traditional chemotherapy often led to collateral damage, affecting both cancerous and healthy cells. However, precision medicine allows for a more personalized approach, taking into account the unique genetic makeup of an individual's cancer. This approach enables oncologists to prescribe drugs that specifically target the molecular and genetic abnormalities driving the growth of cancer cells.

The rise of genomics and next-generation sequencing technologies has empowered researchers to identify specific genetic mutations associated with various types of cancer. Pharmaceutical companies are increasingly developing drugs that target these specific mutations, leading to more effective and less toxic treatment options. As a result, the market for targeted anticancer therapies is expanding rapidly, providing patients with more tailored and efficient treatment regimens.

Artificial intelligence is revolutionizing drug discovery and development, significantly accelerating the identification and optimization of potential anticancer compounds. Machine learning algorithms can analyze vast datasets, including genomic information, clinical trial data, and drug interactions, to identify novel drug candidates and predict their efficacy. AI is also playing a crucial role in drug repurposing, identifying existing drugs that could be repurposed for anticancer purposes. This approach not only saves time and resources but also expedites the availability of new treatment options. The integration of AI in drug discovery is fostering innovation and efficiency in the development of anticancer drugs, contributing to the overall growth of the market.

Early and accurate diagnosis is essential for effective cancer treatment. Recent technological advancements in diagnostic imaging, liquid biopsy, and molecular diagnostics have improved the precision and speed of cancer diagnosis. Liquid biopsy, for example, allows for the detection of circulating tumor DNA in a patient's blood, providing a non-invasive method for monitoring cancer progression and treatment response. Advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors, aiding in treatment planning and monitoring.

Segmental Insights

Indication Insights

Based on indication, breast cancer emerged as the fastest growing segment in the global market for Anticancer Drug in 2023. Breast cancer persists as a significant global health concern, impacting millions of women and, in rare instances, men. The escalating occurrence of risk elements like aging, hormonal shifts, and lifestyle determinants has fueled the upsurge in breast cancer cases. Its prominence in the worldwide anticancer pharmaceutical market stems from its pervasive prevalence and the ongoing endeavors to devise improved and precision-targeted treatments. Pharmaceutical enterprises have acknowledged the substantial market prospects and have made substantial investments in research and development to introduce pioneering therapies for individuals affected by breast cancer.

End User Insights

Based on end user, the Hospitals & Clinics segment is projected to experience rapid growth in the Global Anticancer Drug Market during the forecast period. Hospitals and clinics are actively involved in collaborations with pharmaceutical companies and research institutions to advance the development of novel anticancer drugs. Clinical trials conducted in hospital settings play a crucial role in evaluating the safety and efficacy of new therapies, contributing valuable data to the global anticancer drug market. These collaborations facilitate the seamless integration of research and clinical practice, fostering an environment of innovation in cancer treatment. Patients benefit from access to cutting-edge therapies, and healthcare providers gain insights that contribute to ongoing advancements in the field.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Anticancer Drug Market in 2023, holding the largest market share in terms of value. North America, particularly the United States, has a well-established reputation for leading advancements in pharmaceutical research and development. The region hosts numerous top-tier research institutions, biotechnology companies, and pharmaceutical giants that invest significantly in developing cutting-edge anticancer drugs. The collaboration between academia, private enterprises, and government agencies has created a fertile ground for innovation, leading to the discovery of novel therapies. The United States Food and Drug Administration (FDA) plays a pivotal role in the global pharmaceutical landscape. Its stringent yet efficient regulatory processes ensure that only safe and effective drugs enter the market. The FDA's approval is often seen as a gold standard globally, giving North American pharmaceutical companies a competitive edge. This regulatory framework has facilitated the timely approval and market launch of several groundbreaking anticancer drugs, reinforcing the region's dominance.

Key Market Players

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Novartis AG

Pfizer Inc.

Bristol-Myers Squibb Company

GlaxoSmithKline plc.

Eli Lilly and Company (India) Pvt. Ltd.

AstraZeneca plc

Sanofi S.A.

Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

Breast Cancer Blood Cancer Prostate Cancer Gastrointestinal Cancer Gynaecologic Cancer Lung Cancer Others

Anticancer Drug Market, By Drug:

Cytotoxics Hormonal Therapy Targeted Therapy Others

Anticancer Drug Market, By Route of Administration:

Oral Parenteral Others

Anticancer Drug Market, By End User:

Hospitals & Clinics Ambulatory Care Centers Others

Anticancer Drug Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Drug Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anticancer Drug Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others)
  • 4.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
  • 4.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 4.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.5. By Region
  • 4.2.6. By Company (2023)
• 4.3. Market Map

5. Asia Pacific Anticancer Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication
  • 5.2.2. By Drug
  • 5.2.3. By Route of Administration
  • 5.2.4. By End User
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Anticancer Drug Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Indication
      • 5.3.1.2.2. By Drug
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By End User
  • 5.3.2. India Anticancer Drug Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Indication
      • 5.3.2.2.2. By Drug
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By End User
  • 5.3.3. Australia Anticancer Drug Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Indication
      • 5.3.3.2.2. By Drug
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By End User
  • 5.3.4. Japan Anticancer Drug Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Indication
      • 5.3.4.2.2. By Drug
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By End User
  • 5.3.5. South Korea Anticancer Drug Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Indication
      • 5.3.5.2.2. By Drug
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By End User

6. Europe Anticancer Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Drug
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Anticancer Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Drug
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Germany Anticancer Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Drug
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Spain Anticancer Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Drug
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User
  • 6.3.4. Italy Anticancer Drug Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Drug
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By End User
  • 6.3.5. United Kingdom Anticancer Drug Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Drug
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By End User

7. North America Anticancer Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Drug
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Anticancer Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Drug
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. Mexico Anticancer Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Drug
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Canada Anticancer Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Drug
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User

8. South America Anticancer Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Drug
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Anticancer Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Drug
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. Argentina Anticancer Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Drug
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Colombia Anticancer Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Drug
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User

9. Middle East and Africa Anticancer Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Drug
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Anticancer Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Drug
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Saudi Arabia Anticancer Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Drug
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. UAE Anticancer Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Drug
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Anticancer Drug Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Drug
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
  • 14.1.1. Company Snapshot
  • 14.1.2. Product & Services
  • 14.1.3. Financials (In case of listed)
  • 14.1.4. Recent Developments
  • 14.1.5. SWOT Analysis
• 14.2. Genentech, Inc.
• 14.3. Novartis AG
• 14.4. Pfizer Inc.
• 14.5. Bristol-Myers Squibb Company
• 14.6. GlaxoSmithKline plc.
• 14.7. Eli Lilly and Company (India) Pvt. Ltd.
• 14.8. AstraZeneca plc
• 14.9. Sanofi S.A.
• 14.10.Bayer AG

15. Strategic Recommendations

16. About Us & Disclaimer